Literature DB >> 27890521

Financial incentives for diabetes prevention in a Medicaid population: Study design and baseline characteristics.

Jay Desai1, Gretchen Taylor2, Gabriela Vazquez-Benitez3, Sara Vine4, Julie Anderson3, Joyce E Garrett5, Todd Gilmer6, Houa Vue-Her2, Jeff Schiff5, Sarah Rinn5, Katelyn Engel2, Amy Michael2, Patrick J O'Connor3.   

Abstract

BACKGROUND: Medicaid beneficiaries at high risk for diabetes can benefit from the Diabetes Prevention Program (DPP) lifestyle intervention. The We Can Prevent Diabetes (WCPD) trial examined whether financial incentives are more effective than no financial incentives in sustaining participation in the DPP and increasing weight loss. Here we describe the study design and baseline characteristics.
METHODS: The WCPD was a 3-arm group-randomized controlled trial. Medicaid beneficiaries were aged 18 to 74years, had prediabetes or gestational diabetes, and were overweight or obese. Subjects enrolled from 13 primary care clinics into groups of 8 to 15 participants. Participants received the 12-month DPP delivered by the YMCA or trained clinic staff, free of costs. Participants from groups randomized into the intervention conditions were eligible to receive incentives up to $520 by attending sessions and meeting weight loss goals.
RESULTS: The WCPD enrolled 1154 participants into 98 groups. Among the 847 attending at least one DPP session, 71.2% were women; the mean age was 48.3years; 79.3% were obese; and 87.6% entered the study with an elevated HbA1c or fasting plasma glucose. Participants' primary languages were Somali (21.0%), Hmong (3.1%), Spanish (2.2%), or English (72.4%).
CONCLUSIONS: The WCPD trial demonstrated that a collaborative approach with primary care clinics and the YMCA can efficiently identify, enroll, and deliver the 12-month DPP to Medicaid beneficiaries. If the WCPD incentive arms increase attendance and weight loss, the use of financial incentives may be an avenue for engaging low-income, high-risk patients in lifestyle change.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes prevention; Incentives; Medicaid; Primary care

Mesh:

Substances:

Year:  2016        PMID: 27890521     DOI: 10.1016/j.cct.2016.11.007

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  5 in total

1.  Cost-Effectiveness of a Community-Based Diabetes Prevention Program with Participation Incentives for Medicaid Beneficiaries.

Authors:  Todd Gilmer; Patrick J O'Connor; Jeffrey S Schiff; Gretchen Taylor; Gabriela Vazquez-Benitez; Joyce E Garrett; Houa Vue-Her; Sarah Rinn; Julie Anderson; Jay Desai
Journal:  Health Serv Res       Date:  2018-05-16       Impact factor: 3.402

2.  Effect of Health Plan Financial Incentive Offering on Employees with Prediabetes.

Authors:  Anita D Misra-Hebert; Bo Hu; Phuc H Le; Michael B Rothberg
Journal:  Am J Med       Date:  2017-10-09       Impact factor: 4.965

3.  Using a RE-AIM framework to identify promising practices in National Diabetes Prevention Program implementation.

Authors:  Kunthea Nhim; Stephanie M Gruss; Deborah S Porterfield; Sara Jacobs; Wendi Elkins; Elizabeth T Luman; Susan Van Aacken; Patricia Schumacher; Ann Albright
Journal:  Implement Sci       Date:  2019-08-14       Impact factor: 7.327

4.  The effect of individual and mixed rewards on diabetes management: A feasibility randomized controlled trial.

Authors:  J Jaime Miranda; María Lazo-Porras; Antonio Bernabe-Ortiz; M Amalia Pesantes; Francisco Diez-Canseco; Socorro Del Pilar Cornejo; Antonio J Trujillo
Journal:  Wellcome Open Res       Date:  2019-02-05

5.  The effects of financial incentives on diabetes prevention program attendance and weight loss among low-income patients: the We Can Prevent Diabetes cluster-randomized controlled trial.

Authors:  Jay R Desai; Gabriela Vazquez-Benitez; Gretchen Taylor; Sara Johnson; Julie Anderson; Joyce E Garrett; Todd Gilmer; Houa Vue-Her; Sarah Rinn; Katelyn Engel; Jeff Schiff; Patrick J O'Connor
Journal:  BMC Public Health       Date:  2020-10-21       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.